The FDA is expected to decide on treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine.
Pharmaceutical Technology on MSN2d
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKDThe US Food and Drug Administration (FDA) has approved scPharmaceuticals’ supplemental new drug application (sNDA) for ...
The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant ...
Pharmaceuticals (SCPH) announced that the FDA has approved the supplemental new drug application for Furoscix to expand the indication to ...
Submission is supported by positive results from the Phase III REGENCY trial, which demonstrated that nearly half of patients ...
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s Supplemental Biologics License Application (sBLA) for ...
"In people with lupus nephritis, Gazyva/Gazyvaro demonstrated a complete renal response benefit, a meaningful clinical ...
The FDA advances in multiple cancer types, and researchers assess potential impacts of funding freezes on cancer research.
Presented 48-month data from the GALE extension study at The Macula Society Annual Meeting in February 2025 demonstrating that early treatment with SYFOVRE leads to preservation of retinal tissue at ...
The US Food and Drug Administration has accepted Sobi’s supplemental biologics licence application for Gamifant ...
The U.S. Food and Drug Administration (FDA) has accepted Sobi’s supplemental Biologics License Application (sBLA) for ...
Topical roflumilast, 0.05%, is under consideration for treating mild to moderate atopic dermatitis in children aged 2-5 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback